New antibiotics from genetically engineered actinomycetes. I. 2-Norerythromycins, isolation and structural determinations

J B McAlpine; J S Tuan; D P Brown; K D Grebner; D N Whittern; A Buko; L Katz

doi:10.7164/antibiotics.40.1115

New antibiotics from genetically engineered actinomycetes. I. 2-Norerythromycins, isolation and structural determinations

J Antibiot (Tokyo). 1987 Aug;40(8):1115-22. doi: 10.7164/antibiotics.40.1115.

Authors

J B McAlpine¹, J S Tuan, D P Brown, K D Grebner, D N Whittern, A Buko, L Katz

Affiliation

¹ Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064.

PMID: 3479411
DOI: 10.7164/antibiotics.40.1115

Abstract

Novel macrolide antibiotics have been isolated from a genetically manipulated actinomycete. The major components produced have been isolated and identified as 2-norerythromycins A, B, C and D by mass spectrometry and extensive 1D and 2D NMR experiments.

MeSH terms

Actinomycetaceae / analysis*
Actinomycetaceae / genetics
Anti-Bacterial Agents / isolation & purification*
Erythromycin / analogs & derivatives
Genetic Engineering
Magnetic Resonance Spectroscopy
Microbial Sensitivity Tests
Streptomyces / genetics

Substances

Anti-Bacterial Agents
Erythromycin